Table 1.
Summary of patient and clinical characteristics
| Variables | Bu-Mel (n = 32) | Mel (n = 30) | P |
|---|---|---|---|
| Age at auto-HCT, y | 32 | 30 | .28 |
| Median (range), y | 61.4 (31.7-70.6) | 59.8 (38.8-69.5) | |
| Sex, n (%) | |||
| Male | 16 (50) | 18 (60) | .46 |
| Female | 16 (50) | 12 (40) | |
| R-ISS, n (%) | |||
| I | 6 (22) | 8 (38) | .39 |
| II | 17 (63) | 9 (43) | |
| III | 4 (15) | 4 (19) | |
| Missing | 5 | 9 | |
| HR features (IMWG), n (%) | |||
| Individual | |||
| del(17p) | 11 (34) | 8 (27) | |
| Gain 1q | 18 (56) | 17 (57) | |
| Copy number 3 | 14 | 8 | |
| Copy number ≥4 | 1 | 3 | |
| Not available | 3 | 6 | |
| t(4;14) | 6 (19) | 4 (13) | |
| del(13q) (karyotype) | 6 (19) | 8 (27) | |
| Combined | .61 | ||
| del(17p)/Gain 1q (copy number ≥ 4)/t(4;14) | 17 (55) | 14 (47) | |
| Other | 14 (45) | 16 (53) | |
| Missing | 1 | 0 | |
| Serum LDH | |||
| Normal | 19 (83) | 19 (86) | 1.00 |
| Abnormal | 4 (17) | 3 (14) | |
| Missing | 9 | 8 | |
| HCT-CI, n (%) | |||
| 0 | 11 (34) | 14 (47) | .23 |
| 1-2 | 8 (25) | 10 (33) | |
| ≥3 | 13 (41) | 6 (20) | |
| Response to induction, n (%) | |||
| sCR/CR | 6 (19) | 4 (13) | .55 |
| nCR | 3 (9) | 1 (3) | |
| VGPR | 9 (28) | 11 (37) | |
| PR | 14 (44) | 12 (40) | |
| SD | 0 | 2 (7) | |
| Maintenance regimen, n (%) | |||
| Lenalidomide | 14 (44) | 8 (27) | .69 |
| Lenalidomide and elotuzumab | 4 (13) | 5 (17) | |
| Lenalidomide and ixazomib | 1 (3) | 3 (10) | |
| Lenalidomide and dexamethasone | 2 (6) | 1 (3) | |
| Bortezomib | 3 (9) | 7 (23) | |
| IRD | 2 (6) | 1 (3) | |
| KRD | 1 (3) | 2 (7) | |
| VRD | 2 (6) | 1 (3) | |
| None | 3 (9) | 2 (7) | |
| Induction regimen, n (%) | |||
| VRD | 19 (59) | 17 (59) | .99 |
| VCD | 6 (19) | 5 (17) | |
| KRD | 4 (13) | 3 (10) | |
| Vd | 3 (9) | 3 (10) | |
| CBAD | 0 | 1 (3) | |
| Missing | 0 | 1 |
CBAD, cyclophosphamide, bortezomib, adriamycin, and dexamethasone; CR, complete response; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; IMWG, International Myeloma Working Group; IRD, ixazomib, lenalidomide, and dexamethasone; KRD, carfilzomib, lenalidomide, and dexamethasone; LDH, lactate dehydrogenase; nCR, near CR; PR, partial response; sCR, stringent complete response; SD, stable disease; VCD, bortezomib, cyclophosphamide, and dexamethasone; Vd, bortezomib and dexamethasone; VGPR, very good partial response; VRD, .